Adverse Event Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Adverse Event clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Not Applicable

Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma

Quality of LifeObjective Response RatePathological Complete Remission+1 more
The Second Hospital of Shandong University25 enrolled1 locationNCT07430579
Recruiting

Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients

Solid TumorsSjogren SyndromeImmune-related Adverse Events+3 more
Hospital Universitario Araba300 enrolled1 locationNCT07249060
Recruiting
Not Applicable

Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis

Peritoneal DialysisAdverse EventModerate-to-severe Pruritus+1 more
Guangdong Provincial People's Hospital93 enrolled1 locationNCT07098351
Recruiting
Phase 2

Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)

Advanced MelanomaDiarrheaImmune-related Adverse Event+1 more
AHS Cancer Control Alberta20 enrolled1 locationNCT05663775
Recruiting

Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients

Gastric CancerImmunotherapyAdverse Event+2 more
Qinghai Red Cross Hospital100 enrolled1 locationNCT06915389
Recruiting
Phase 4

Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes

Blood PressureDiabetes Mellitus, Type 2Adverse Event+2 more
XueQing Yu11,414 enrolled1 locationNCT03264352
Recruiting

Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer

Neoadjuvant TherapydMMR Colorectal CancerImmune-related Adverse Event
Xijing Hospital100 enrolled1 locationNCT06613165
Recruiting
Phase 2

SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)

Mmr DeficiencyImmune-related Adverse EventEndometrial Cancer Stage I+1 more
Queensland Centre for Gynaecological Cancer10 enrolled3 locationsNCT06278857
Recruiting
Not Applicable

The Effect of Serum Ferritin in irAE

Acute LeukemiaMalignant Solid TumorsImmune-related Adverse Event+1 more
Tianjin Medical University Cancer Institute and Hospital1,500 enrolled1 locationNCT06702566
Recruiting
Phase 2

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Cervical CarcinomaImmunotherapyImmune Checkpoint Inhibitor+6 more
Lei Li92 enrolled1 locationNCT05311566